| A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations Y Yamamoto, PA Välitalo, DJ van den Berg, R Hartman, W van den Brink, ... Pharmaceutical research 34, 333-351, 2017 | 88 | 2017 |
| Current and future nutritional strategies to modulate inflammatory dynamics in metabolic disorders W van den Brink, J van Bilsen, K Salic, FPM Hoevenaars, L Verschuren, ... Frontiers in nutrition 6, 129, 2019 | 62 | 2019 |
| Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics ECM de Lange, W van den Brink, Y Yamamoto, WEA de Witte, YC Wong Expert Opinion on Drug Discovery 12 (12), 1207-1218, 2017 | 56 | 2017 |
| Whole grain wheat consumption affects postprandial inflammatory response in a randomized controlled trial in overweight and obese adults with mild hypercholesterolemia in the … FPM Hoevenaars, D Esser, S Schutte, MG Priebe, RJ Vonk, ... The Journal of nutrition 149 (12), 2133-2144, 2019 | 51 | 2019 |
| Digital biomarkers for personalized nutrition: predicting meal moments and interstitial glucose with non-invasive, wearable technologies WJ van den Brink, TJ van den Broek, S Palmisano, S Wopereis, ... Nutrients 14 (21), 4465, 2022 | 28 | 2022 |
| Digital resilience biomarkers for personalized health maintenance and disease prevention W van den Brink, R Bloem, A Ananth, T Kanagasabapathi, A Amelink, ... Frontiers in Digital Health 2, 614670, 2021 | 21 | 2021 |
| Access to the CNS: biomarker strategies for dopaminergic treatments WJ van den Brink, S Palic, I Köhler, ECM de Lange Pharmaceutical research 35 (3), 64, 2018 | 20 | 2018 |
| Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats WJ Van den Brink, J Elassaiss-Schaap, B Gonzalez-Amoros, AC Harms, ... European Journal of Pharmaceutical Sciences 109, 431-440, 2017 | 15 | 2017 |
| Revealing the neuroendocrine response after remoxipride treatment using multi-biomarker discovery and quantifying it by PK/PD modeling WJ van den Brink, YC Wong, B Gülave, PH van der Graaf, ECM de Lange The AAPS Journal 19, 274-285, 2017 | 15 | 2017 |
| Obese older type 2 diabetes mellitus patients with muscle insulin resistance benefit from an enriched protein drink during combined lifestyle intervention: the probe study WJ Pasman, RG Memelink, J de Vogel-Van den Bosch, ... Nutrients 12 (10), 2979, 2020 | 14 | 2020 |
| Next generation health claims based on resilience: the example of whole-grain wheat F Hoevenaars, JW van Der Kamp, W van Den Brink, S Wopereis Nutrients 12 (10), 2945, 2020 | 14 | 2020 |
| Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics WJ Van den Brink, T Hankemeier, PH van der Graaf, ECM de Lange Expert Opinion on Drug Discovery 13 (6), 539-550, 2018 | 13 | 2018 |
| Exploring the potential of personalized dietary advice for health improvement in motivated individuals with premetabolic syndrome: pretest-posttest study S van der Haar, FPM Hoevenaars, WJ van den Brink, T van den Broek, ... JMIR Formative Research 5 (6), e25043, 2021 | 11 | 2021 |
| Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents W van den Brink, A Emerenciana, F Bellanti, O Della Pasqua, ... Toxicology and Applied Pharmacology 320, 51-59, 2017 | 10 | 2017 |
| Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D2 receptor activation using multi‐biomarker pharmacokinetic/pharmacodynamic modelling WJ van den Brink, DJ van den Berg, FEM Bonsel, R Hartman, YC Wong, ... British Journal of Pharmacology 175 (19), 3832-3843, 2018 | 8 | 2018 |
| Mechanism-based biomarker prediction for low-grade inflammation in liver and adipose tissue JHM van Bilsen, W van den Brink, AM van den Hoek, R Dulos, ... Frontiers in Physiology 12, 703370, 2021 | 7 | 2021 |
| Carcinogenicity of biopharmaceuticals M Dempster, K Siezen, B Braak, W van den Brink, A Emerenciana, ... Genotoxicity and Carcinogenicity Testing of Pharmaceuticals, 125-157, 2015 | 4 | 2015 |
| Blood‐based biomarkers of quinpirole pharmacology: cluster‐based PK/PD and metabolomics to unravel the underlying dynamics in rat plasma and brain WJ van den Brink, R Hartman, DJ van den Berg, G Flik, ... CPT: Pharmacometrics & Systems Pharmacology 8 (2), 107-117, 2019 | 3 | 2019 |
| Feasibility of digital phenotyping based on continuous glucose monitoring to support personalized lifestyle medicine in type 2 diabetes WJ van den Brink, TJ van den Broek, S Wopereis, S Difrancesco, ... Maturitas 194, 108188, 2025 | | 2025 |
| Sleep as a window of cardiometabolic health: The potential of digital sleep and circadian biomarkers WJ van den Brink, JE Oosterman, DJ Smid, HJ de Vries, DE Atsma, ... DIGITAL HEALTH 11, 20552076241288724, 2025 | | 2025 |
